NCT00610103View on ClinicalTrials.gov

Phase 2 Clinical Study of KW-6500 in Parkinson's Disease Patients With Motor Response Complication on Levodopa Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Parkinson's Disease
Interventions
DRUG

apomorphine hydrochloride

Apomorphine hydrochloride (started at 1 mg and titrated to a maximum of 6 mg) is subcutaneously administered.

Trial Locations (4)

Unknown

Tōon

Tsukuba

Bunkyo-ku

Fukuoka

All Listed Sponsors
lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT00610103 - Phase 2 Clinical Study of KW-6500 in Parkinson's Disease Patients With Motor Response Complication on Levodopa Therapy | Biotech Hunter | Biotech Hunter